Completed PHASE2 INTERVENTIONAL 4-arm NCT00570765

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis

Sponsor: Intercept Pharmaceuticals

Interventions Obeticholic Acid (OCA) Placebo

Updated 10 times since 2017 Last updated: May 28, 2021 Started: Jan 17, 2008 Primary completion: Sep 21, 2010 Completion: Sep 25, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Liver Cirrhosis, Biliary and is currently completed. Intercept Pharmaceuticals leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Mar 2021 — Sep 2021 [monthly]

Completed PHASE2
Jan 2021 — Mar 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Intercept Pharmaceuticals

Data source: Intercept Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Detroit, United States , Edgbaston, United Kingdom , Edinburgh, United Kingdom , Edmonton, Canada , Frankfurt, Germany , Graz, Austria , Hamburg, Germany , Hampstead, United Kingdom , Hanover, Germany and 11 more locations